Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congresstm 2021


Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company's liver disease programs will be presented at The International Liver Congresstm 2021 (ILC) taking place from June 23-26. The breadth of data reflects Gilead's continued commitment to liver disease, including the recent expansion into chronic hepatitis delta virus (HDV), with Hepcludex® (bulevertide) as the first-in-class treatment for people with HDV conditionally approved in Europe. Gilead will also present clinical and real-world data on global efforts to support the World Health Organization's goal of hepatitis C (HCV) elimination, the impact of treatment in chronic hepatitis B infection (HBV) and ongoing research in nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).

"We're excited to join the liver community at this year's International Liver Congress and in particular to share these Phase 3 data which reinforce the potential of Hepcludex for the treatment of HDV, the most severe form of chronic viral hepatitis," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "We continue to strive to address some of the most substantial challenges in liver diseases, and we look forward to leveraging our expertise to transform the trajectory for people living with HDV."

Gilead will present interim data on Hepcludex for the treatment of HDV from Phase 3 and Phase 2b clinical trials, which reinforce the safety and efficacy data that was used for the European Medicines Agency (EMA) conditional approval in 2020.

Interim results from the Phase 3 study (MYR301) evaluating the efficacy of Hepcludex monotherapy at low and high doses will be presented as a late-breaking poster presentation (LBP-2730) and broadcast live as part of the ILC's Official Press Program on June 24 at 9:00 am EDT/15:00 pm CET. Additionally, interim findings from the Phase 2b study (MYR204) will be presented, evaluating the safety and efficacy of Hepcludex monotherapy and in combination with peginterferon alfa-2a. Hepcludex is not approved by the U.S. Food and Drug Administration (FDA).

"HDV only occurs in people co-infected with HBV and leads to more serious liver disease than HBV alone, complicating the diagnosis and treatment journey for this patient population," said Tarik Asselah, Professor of Hepatology at Hôpital Beaujon, Clichy, and at the University Paris, and Head of Viral Hepatitis Team at INSERM UMR1149, France. "The data on bulevertide to be presented at ILC provide significant progress and promise for people living with chronic HDV, who have previously had very limited treatment options and a poor prognosis."

HCV Elimination Efforts

Gilead will present real-world data from HCV screening and linkage to care initiatives which underscore the company's dedication to global HCV elimination efforts. Additional results will be presented showcasing the potential of Epclusa® (400 mg sofosbuvir/100 mg velpatasvir) in the test-and-treat strategy for HCV management based on a simplified monitoring algorithm for appropriate patients.

HBV Treatment and Functional Cure

Data on HBV will highlight the long-term results of switching to Vemlidy® (tenofovir alafenamide 25 mg, TAF). Data will also be presented on Gilead's ongoing pursuit toward HBV functional cure.

Select accepted abstracts being presented at the ILC include:

Abstract

Abstract Title

HDV

 

OS-2717

 

Safety and efficacy of bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 Phase 2b study

LBP-2730

 

Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the Phase 3 MYR301 study

PO-665

 

Transcriptomic analyses reveal variation of liver inflammation across phases of chronic hepatitis B infection

HCV

 

PO-377

 

Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients

PO-1431

 

Value assessment of sofosbuvir-based regimens for (chronic) hepatitis C in Spain

PO-1426

 

A discrete choice experiment about patients' and clinicians' preferences for the meet-test-treat approach to HCV management

OS-199

 

Get Tested LeEDs: Clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs)

PO-1341

 

Active search to retrieve lost-to follow-up HCV patients (RELINK-C strategy): health and economic value

PO-2020

 

Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients able to start direct-acting antiviral treatment

HBV

PO-2338

 

Switching from TDF and/or other oral antivirals to TAF in virally suppressed chronic hepatitis B patients with hepatic impairment: 2 year data efficacy & safety results from a Phase 2 study

PO-2395

 

Switching from TDF and/or other oral antivirals to TAF in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: 96 week efficacy & safety results from a Phase 2 study

OS-2283

 

Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF) in children with chronic hepatitis B (CHB): final results from a placebo-controlled trial

PO-2429

 

Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B

PO-2422

 

Safety, efficacy, & pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a Phase 2 collaboration study

PO-1309

 

Alanine aminotransferase flares and seroclearance in chronic hepatitis B virus patients

OS-2225

 

Predictive immune biomarkers of persistent HBV DNA suppression and low replicative state after treatment discontinuation in CHB patients

NASH

OS-1611

 

AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints

OS-1746

 

Cilofexor and firsocostat treatment is associated with widespread changes in the hepatic transcriptome in NASH patients with advanced fibrosis

PO-757

 

Fenofibrate is safe and mitigates increases in serum triglycerides in NASH patients treated with the combination of the ACC inhibitor firsocostat and the FXR agonist cilofexor: A randomized trial

PO-756

 

Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared to semaglutide alone in patients with non-alcoholic steatohepatitis

PO-1714

 

Liver stiffness by vibration-controlled transient elastography predicts disease progression in patients with advanced fibrosis due to NASH

PO-1568

 

Longitudinal variability of noninvasive tests of fibrosis: Implications for treatment response monitoring in patients with NASH

PO-756

 

Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared to semaglutide alone in patients with non-alcoholic steatohepatitis

PO-1831

 

Combinations of an acetyl CoA carboxylase inhibitor, FXR agonist and GLP-1R agonist inhibits fibrosis progression in the rat choline-deficient, L-amino acid defined, high-fat diet model of advanced fibrosis

PO-866

 

Comparing traditional machine learning and deep learning models to Fibrosis-4 index in the prediction of non-alcoholic fatty liver disease-associated liver fibrosis

PSC

PO-1644

 

A deep learning approach to analysis of MRCP images predicts clinical events and progression to cirrhosis in patients with primary sclerosing cholangitis

For more information, including a complete list of abstract titles being presented at the meeting, please visit: https://easl.eu/event/the-international-liver-congress-2021/scientific-programme/.

Hepcludex has been granted PRIority MEdicines (PRIME) scheme eligibility by EMA for the treatment of HDV infection and Breakthrough Therapy designation by the U.S. FDA. Bulevirtide is an investigational agent in the U.S. and outside of the European Economic Area; in these regions the safety and efficacy have not been established.

Cilofexor, firsocostat, inarigivir and selgantolimod are investigational compounds and are not approved by the FDA or any other regulatory authority; their safety and efficacy have not been established.

Please see below for the U.S. Indications and Important Safety Information, including BOXED WARNINGS, for Epclusa and Vemlidy.

U.S. Important Safety Information for Epclusa

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Contraindications

If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

Adverse Reactions

Drug Interactions

Indication

EPCLUSA is indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

U.S. Important Safety Information and Indication for Vemlidy

BOXED WARNING: POST TREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B

Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Warnings and Precautions

Adverse Reactions

Drug Interactions

Dosage and Administration

Indication

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

About HDV

Chronic hepatitis delta virus (HDV) is the most severe form of viral hepatitis and can have mortality rates as high as 50% within 5 years in cirrhotic patients. HDV occurs only as a co-infection in individuals who have hepatitis B virus (HBV). It is estimated that at least 12 million people worldwide are likely currently co-infected with HDV and HBV. HDV co-infection is associated with a faster progression to liver fibrosis, cirrhosis, hepatic decompensation and an increased risk of liver cancer and death. In the U.S. and Europe, there are approximately more than 230,000 people living with HDV, however it remains underdiagnosed globally.

About Gilead Sciences in Liver Disease

For more than 20 years, Gilead has sought to address some of the biggest challenges in liver disease. The company has transformed the trajectory of many liver diseases through a relentless pursuit of innovation and pioneering access programs to bring meaningful therapies to people around the world. More work is required, and Gilead is committed to advancing innovative therapeutics to address the most pressing unmet needs in liver disease and overcoming barriers to better care.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, including those involving Hepcludex, Epclusa, Vemlidy, cilofexor, firsocostat, inarigivir and selgantolimod; the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving Hepcludex, Epclusa, Vemlidy, cilofexor, firsocostat, inarigivir and selgantolimod; the possibility that Gilead may make a strategic decision to discontinue development of cilofexor, firsocostat, inarigivir, selgantolimod and other investigational compounds and as a result, the compounds may never be successfully commercialized; Gilead's ability to receive regulatory approvals in a timely manner or at all, including FDA or EMA approval of Hepcludex, and the risk that any such approvals may be subject to significant limitations on use; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. Prescribing Information for Epclusa and Vemlidy including BOXED WARNINGS, are available at www.gilead.com.

Hepcludex, Epclusa, Vemlidy, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.


These press releases may also interest you

at 15:20
Aventiv Technologies, a communications and technology business serving the incarcerated, their friends and family, and state and local correctional facilities, today announced an agreement...

at 15:15
Dentsu announced today the official launch of Merkury for Media, the network's latest offering within its unrivaled global data, identity, and insights platform, Merkury. The new...

at 15:11
The technology service provider market is at a crucial turning point, marked by exponential technological innovation,...

at 15:10
ServiceChannel, the leading platform for the procurement and delivery of facilities services, announced today the introduction of new solutions that empower business operators to maximize their facilities investments. The Spring 2024 Product...

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:01
G FUEL and Gearbox Entertainment Company celebrate gaming icon Duke Nukem with Ego Boost, a new zero-sugar Energy Formula now available at GFUEL.com. Fans can purchase the cherry, orange, and pomegranate flavor as a 40-serving standalone powder Tub...



News published on and distributed by: